Overall, the safety profile of the combination therapy was consistent with previous clinical trials with nintedanib and the known safety profile of docetaxel, with the most common drug-related AEs being myelotoxicity (neutropenia and leukopenia), liver enzyme elevations (increased AST and ALT), gastrointestinal AEs (diarrhea and nausea), and alopecia. The gene discussed is GPT; the disease is neutropenia.